Intramuscular glucagon used to prevent IV glucose infusion i
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The success rate of intramuscular (IM) glucagon in preventing the need for IV glucose was investigated and its glycemic effect was identified in a report. The retrospective research included 158 consecutive term neonates with glucagon-treated feeding-resistant hypoglycemia.

--After glucagon, blood glucose (BG) increased by 25.9 ± 17.1, 42.1 ± 21.1, and 39.2 ± 28.3 mg/dL (1.4 ± 0.9, 2.3 ± 1.2, 2.2 ± 1.6 mmol/L) in all but 1 child at 30, 60 and 120 mins, respectively.

--In multivariable logistic regression, glucagon success was dependent upon gender (increased male risk), meeting American Academy of Pediatrics (AAP) criteria for immediate IV glucose, birth weight, and delta glucose concentration at 60 min.

--After IM glucagon, 24 out of 49 infants that met AAP criteria for immediate IV glucose (49%) ended up not requiring any additional intervention.

In fact, in hypoglycemic infants, Glucagon almost invariably raises Blood Glucose and decreases the number of infants needing immediate IV glucose infusion therapy by half.

Source: https://www.nature.com/articles/s41372-021-00925-x
Like
Comment
Share